Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its third quarter ended September 30, 2025 and the ...
First clinical data disclosure for CB-011 highlights its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory ...
Strong operating performance delivered double-digit growth on both the top and bottom lineRaising full year 2025 guidance and issuing full year 2026 guidanceAnnounces business combination with Husky ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback